BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of 28 found
  Current Search:  friedreich: 28, ataxia: 58     

HTML
100%
Neurodegenerative Disease Therapy: Researchers from University of California, Department of Neurology detail n
Researchers from University of California, Department of Neurology detail new studies and findings in the area of neurodegenerative disease therapy Researchers detail in 'Functional genomic analysis of frataxin deficiency reveals tissue...
NewsRX:  Jul 2 2009 3:05AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Idebenone Well Tolerated in Patients With Friedreich's Ataxia: Presented at ENS
my personal edition> neurologic other > news E-Mail this DGDispatch to a colleague DGDispatch MILAN, Italy -- June 25, 2009 -- In patients with the rare autosomal recessive disorder Friedreich's ataxia (FRDA),...
Doctors Guide:  Jun 26 2009 11:13PM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to total revenue...

KSLA:  Jun 11 2009 8:58PM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Total revenue for fiscal year 2009 was $29,362,000 compared to total revenue of $19,296,000 for fiscal year 2008 ended March 31, 2008, an increase of $10,066,000 or 52%.

Total revenue for the year was comprised of Protein A product revenue...

Pharma Live:  Jun 11 2009 8:10PM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation Operating expenses for fiscal year 2009 were $25,482,000 compared to $23,574,000, exclusive of the net gain of $40,170,000 from the settlement of our litigation with...
Montana's News Station:  Jun 11 2009 3:25PM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to total revenue...

KOTA Territory News:  Jun 11 2009 2:25PM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to total revenue of $19,296,000 for fiscal year 2008...

San Antonio Business Journal:  Jun 11 2009 11:47AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to...

San Francisco Business Times:  Jun 11 2009 11:45AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to...

Business Journal of Milwaukee:  Jun 11 2009 11:43AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to...

Atlanta Business Chronicle:  Jun 11 2009 11:30AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to total revenue of $19,296,000 for fiscal year 2008...

Phoenix Business Journal:  Jun 11 2009 11:28AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to...

Portland Business Journal:  Jun 11 2009 11:28AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
/PRNewswire-FirstCall via COMTEX/ -- RGEN | Quote | Chart | News | PowerRating -- Repligen Corporation (Nasdaq: RGEN | Quote | Chart | News | PowerRating) today reported results for the fourth quarter and fiscal year 2009, ended March 31,...
TradingMarkets:  Jun 11 2009 11:28AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial
Repligen Corporation today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to total revenue of $19,296,000 for fiscal year 2008 ended March 31,...

PR Newswire via MSN Money:  Jun 11 2009 11:26AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to...

Biz Journals:  Jun 11 2009 11:25AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to...

PR Newswire:  Jun 11 2009 11:21AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to...

Nashville Business Journal:  Jun 11 2009 11:21AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to...

Cincinnati Business Journal:  Jun 11 2009 11:20AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN - News) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000...

PR Newswire via Yahoo!:  Jun 11 2009 11:18AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to...

Columbus Business First:  Jun 11 2009 11:17AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to total revenue...

Stockwatch:  Jun 11 2009 11:13AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to total...

Houston Chronicle:  Jun 11 2009 11:13AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
WALTHAM, Mass., June 11 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the fourth quarter and fiscal year 2009, ended March 31, 2009.

Total revenue for fiscal year 2009 was $29,362,000 compared to...

Street Insider:  Jun 11 2009 11:11AM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Santhera's Stock Plummets on Idebenone Phase III Miss
By Cormac Sheridan BioWorld International Correspondent Shares in Santhera Pharmaceuticals Holding AG plunged 40 percent last week on news that its lead compound Catena (idebenone) missed the primary endpoint in a U.S.

Phase III trial in...

BioWorld:  May 27 2009 4:52PM
Matching: friedreich ataxia
Find similar documents
HTML
100%
Santhera's US phase III IONIA trial in Friedreich's Ataxia fails
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, announced that its US phase III clinical trial evaluating Catena for the treatment of Friedreich's Ataxia missed its...
PharmaBiz:  May 22 2009 12:50PM
Matching: friedreich ataxia
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.